Tumour Registry Lung Cancer (TLK)

N/ACompletedNCT01192919

iOMEDICO AG2,500 enrolled

Overview

Overview of treatment reality in patients with bronchial carcinoma requiring systemic treatment and being treated by office-based oncologists in Germany.

The TLK is a prospective, longitudinal, nation wide cohort study that collects data on the treatment reality of patients with NSCLC and SCLC. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Patients are followed until death or for a maximum of 3 years.

Study Type

OBSERVATIONAL

Enrollment

2,500

Conditions

Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * histologically confirmed Small Cell Lung Cancer (SCLC), Non Small Lung Cancer (NSCLC) or neuroendocrine tumors receiving therapy * written informed consent * start of neoadjuvant, adjuvant or first-line therapy no longer than 4 weeks before informed consent Exclusion Criteria: * patients not receiving any systemic therapy

Outcomes

Primary Outcomes

Documentation of actually used therapy forms in bronchial carcinoma requiring treatment

Time frame: 3 years per patient

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.